Immunology

The programme brought together international and local experts to discuss the evolving understanding of Type 2 inflammation in atopic dermatitis, with a focus on IL-4 and IL-13, disease modification, and the importance of early intervention across different patient populations. 

Nearly 1 in 3 patients with uncontrolled moderate‑to‑severe type 2 asthma achieved clinical remission with dupilumab. Our latest update highlights key QUEST/TRAVERSE data, remission criteria, and implications for practice.

LIBERTY AD CHRONOS was a randomized, double-blind, placebo-controlled trial in adults with 
moderate-to-severe atopic dermatitis

LIBERTY AD SOLO-CONTINUE was a randomized, double-blind, phase 3 clinical trial at 185 sites in North America, Europe, Asia, and Japan.

LIBERTY AD HAFT was a randomized phase 3 trial in adults and adolescents with moderate-to-severe hand and foot atopic dermatitis inadequately controlled with topicals.

Efficacy is shown through real-world evidence, skin bacterial microbiome, trans-epidermal water loss (TEWL), and nonatopic comorbidities.

Significant improvement in Worst Scratch and Itch NRS score, Skin Clearance, and Children’s Dermatology Life Quality Index (CDLQI).

Efficacy is shown through 3 years of disease control, impact on growth curve, and improvement in mental health.​